What Happened to Device IPOs?
This article was originally published in Start Up
Executive Summary
Private-to-public step-up multiples for 1997 device IPOs have fallen dramatically since the offerings of 1996.
You may also be interested in...
Can a Hippo Save the IPO Market for Life Sciences?
A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.